NASDAQ:HOOK - Hookipa Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.14
  • Forecasted Upside: 68.60 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$12.54
▼ -0.11 (-0.87%)
1 month | 3 months | 12 months
Get New Hookipa Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HOOK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HOOK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$21.14
▲ +68.60% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Hookipa Pharma in the last 3 months. The average price target is $21.14, with a high forecast of $28.00 and a low forecast of $16.00. The average price target represents a 68.60% upside from the last price of $12.54.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Hookipa Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/14/2021Morgan StanleyInitiated CoverageOverweight$19.00Low
i
4/8/2021Morgan StanleyInitiated CoverageOverweight$19.00High
i
3/21/2021SVB LeerinkReiterated RatingBuy$28.00Low
i
11/30/2020JMP SecuritiesBoost Price TargetOutperform$19.00 ➝ $25.00High
i
11/3/2020Truist FinancialInitiated CoverageBuy$21.00Low
i
11/3/2020TruistInitiated CoverageBuy$21.00 ➝ $21.00High
i
10/26/2020JMP SecuritiesInitiated CoverageMarket Outperform$19.00Low
i
10/19/2020HC WainwrightReiterated RatingBuy$16.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/16/2020Royal Bank of CanadaReiterated RatingBuy$18.00Low
i
6/17/2020HC WainwrightReiterated RatingBuy$15.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
1/10/2020HC WainwrightReiterated RatingBuy$15.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/13/2019HC WainwrightReiterated RatingBuy$15.00High
i
Rating by D. Chattopadhyay at HC Wainwright
9/27/2019HC WainwrightInitiated CoverageBuy$15.00High
i
Rating by D. Chattopadhyay at HC Wainwright
8/14/2019Royal Bank of CanadaReiterated RatingBuy$23.00Medium
i
5/13/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$17.00Low
i
5/13/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$23.00Low
i
(Data available from 4/19/2016 forward)
Hookipa Pharma logo
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.
Read More

Today's Range

Now: $12.54
$12.12
$12.71

50 Day Range

MA: $12.94
$11.55
$14.70

52 Week Range

Now: $12.54
$7.28
$15.52

Volume

101,200 shs

Average Volume

174,526 shs

Market Capitalization

$325.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Hookipa Pharma?

The following Wall Street research analysts have issued reports on Hookipa Pharma in the last twelve months: HC Wainwright, JMP Securities, Morgan Stanley, Royal Bank of Canada, SVB Leerink LLC, TheStreet, Truist, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for HOOK.

What is the current price target for Hookipa Pharma?

7 Wall Street analysts have set twelve-month price targets for Hookipa Pharma in the last year. Their average twelve-month price target is $21.14, suggesting a possible upside of 68.6%. SVB Leerink LLC has the highest price target set, predicting HOOK will reach $28.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for Hookipa Pharma in the next year.
View the latest price targets for HOOK.

What is the current consensus analyst rating for Hookipa Pharma?

Hookipa Pharma currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HOOK will outperform the market and that investors should add to their positions of Hookipa Pharma.
View the latest ratings for HOOK.

What other companies compete with Hookipa Pharma?

How do I contact Hookipa Pharma's investor relations team?

Hookipa Pharma's physical mailing address is 350 FIFTH AVENUE 72ND FLOOR SUITE 7240, NEW YORK NY, 10118. The company's listed phone number is 431-890-6360 and its investor relations email address is [email protected] The official website for Hookipa Pharma is www.hookipapharma.com.